Move provides greater access to investors, grants, partners and expertise

Cambridge, UK, 21st February 2014. Biosceptre International Limited, the oncology company developing antibodies to target the nf-P2X7 receptor, today announced that has moved operations to the UK, from Australia.

The move comes as Biosceptre enters the next phase of its development. The Company is currently progressing the applications of its unique intellectual property and knowledge of nf-P2X7, including systemic and topical applications for human and veterinary use, across therapeutics, diagnostics and imaging, and immuno-oncology vaccines.

“The move to the UK, in particular Cambridge, gives Biosceptre access to some of the greatest expertise in antibody engineering in the world. This, combined with greater access to capital, European grants, the favourable taxation position for R&D companies, and potential developmental partners on our doorstep, will provide Biosceptre with the greatest chance of commercial success,” said Gavin Currie, CEO of Biosceptre.

Following the move to the UK, Biosceptre will have its headquarters and main research facility in Cambridge, but will also maintain the existing facilities in Sydney, Australia.

Media contact:

Daniel Barton
+61 412 548 824
+1 650 249 4977